83B.F 3SBio Inc
- Market cap
- EUR 4.14B
- P/E
- 4.1x
- P/B
- 1.13x
- ROE
- 31.2%
- Dividend yield
- 1.66%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 83B.F undervalued?
Graham number83B.F trades 54.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
3SBio Inc fundamental analysis
No fundamental analysis for 3SBio Inc yet.
3SBio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About 3SBio Inc
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia. It also provides EPIAO for indications, such as the treatment of anemi…
Full company profile3SBio Inc financial statements
3SBio Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.80B | 3.73B | 4.58B | 5.32B | 5.59B | 6.38B | 6.86B | 7.82B | 9.11B | 17.7B |
| Gross Profit | 2.40B | 3.06B | 3.71B | 4.39B | 4.52B | 5.28B | 5.67B | 6.64B | 7.83B | 16.3B |
| Operating Income | 914M | 1.21B | 1.40B | 1.31B | 1.56B | 1.88B | 2.02B | 2.46B | 2.73B | 10.6B |
| EBITDA | - | 1.49B | 1.96B | 1.67B | 1.06B | 2.26B | 2.76B | 2.53B | 3.30B | 11.4B |
| Net Income | 713M | 935M | 1.28B | 974M | 836M | 1.65B | 1.91B | 1.55B | 2.09B | 8.48B |
| EPS | - | 0.37 | 0.50 | 0.38 | 0.33 | 0.65 | 0.79 | 0.65 | 0.89 | 3.39 |
| Balance Sheet | ||||||||||
| Total Assets | 11.0B | 13.8B | 13.8B | 14.8B | 17.7B | 19.2B | 22.0B | 23.6B | 24.2B | 36.3B |
| Total Liabilities | 4.27B | 6.12B | 4.93B | 4.45B | 4.58B | 4.55B | 6.59B | 7.11B | 6.18B | 5.81B |
| Shareholders' Equity | 6.52B | 7.40B | 8.61B | 9.63B | 10.7B | 12.2B | 13.0B | 14.0B | 15.4B | 27.2B |
| Cash & Short-term Investments | 674M | 2.40B | 1.79B | 2.08B | 3.09B | 2.80B | 2.15B | 2.69B | 2.02B | 15.5B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.00B | 1.07B | 1.15B | 1.89B | 1.34B | 1.58B | 2.18B | 2.08B | 3.20B | 9.67B |
| Capital Expenditure | 466M | 138M | 247M | 471M | 893M | 1.03B | 974M | 704M | 963M | 541M |
| Free Cash Flow | - | 831M | 717M | 1.40B | 363M | 433M | 1.21B | 1.38B | 2.24B | 9.13B |
| Ratios | ||||||||||
| ROE | 10.9% | 12.6% | 14.8% | 10.1% | 7.8% | 13.5% | 14.8% | 11.0% | 13.5% | 31.2% |
| ROA | 6.5% | 6.8% | 9.2% | 6.6% | 4.7% | 8.6% | 8.7% | 6.6% | 8.6% | 23.4% |
| Net Profit Margin | 25.5% | 25.0% | 27.9% | 18.3% | 15.0% | 25.9% | 27.9% | 19.8% | 23.0% | 47.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
3SBio Inc dividends
- Dividend yield
- 1.66%
- Forward dividend
- 0.03 EUR
- Payout ratio
- 6.6%
- Ex-dividend date
- Jul 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 560M | 0.22 | 6.6% |
| 2024 | CNY 555M | 0.24 | 26.6% |
| 2023 | CNY 225M | 0.09 | 14.5% |
| 2022 | CNY 417M | 0.17 | 21.8% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | EUR 16.3M | 0.01 | 1.7% |
| 2018 | EUR 151M | 0.06 | 11.8% |
| 2017 | EUR 151M | 0.06 | 16.1% |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns 3SBio Inc
- Insiders 24.99%
- Institutions 43.71%
- Public & others 31.30%
- Shares outstanding 2.48B
- Free float 1.88B
3SBio Inc company profile
- Company name
- 3SBio Inc
- Ticker
- 83B.F
- ISIN
- KYG8875G1029
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6,068
- Fiscal year end
- December
- Address
- No. 3 A1, Road 10, Shenyang, China
- Phone
- 86 24 2538 6000
- Website
- 3sbio.com
About 3SBio Inc
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia. It also provides EPIAO for indications, such as the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and the reduction of allogeneic blood transfusion in surgery patients; and Yisaipu, a TNF-a inhibitor product for rheumatoid arthritis, ankylosing spondylitis, and psoriasis indications. In addition, the company offers Cipterbin, an anti-HER2 mAb for treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; and Mandi, a minoxidil tincture for androgenetic alopecia and alopecia areata. Further, it develops 608, an anti-IL-17A mAb; SSS20 for patients with ITP and severe Aplastic Anemia; SSS06 for the treatment of adult dialysis patients undergoing erythropoietin therapy with a biweekly dosing interval; 613, for the treatment of acute gouty arthritis; 611, an anti-IL-4R a mAb; and 601A, an anti-VEGF mAb. Additionally, the company is involved in manufacture and sale of pharmaceutical drugs; business management; provision of technical services, investment advisory services, financial services, sports services, clinic services, technology services, and agricultural services; retail of pharmaceuticals; and enterprise management consulting. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
3SBio Inc management
8- Dr. Jing Lou M.D., Ph.D.Co-Founder, Executive Chairman, CEO & President · born 1963
- Dr. Dongmei SuSenior VP & Executive Director · born 1970
- Mr. Xiang HeChief Financial Officer · born 1984
- Ms. Siu Kuen Lai FCIS, FCSCompany Secretary · born 1976
- Mr. Yong XuGeneral Manager of Shenzhen Sciprogen Bio-pharmaceutical Technology Co., Ltd. · born 1965
- Ms. Yanli LiuGeneral Manager of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · born 1981
- Mr. Zheng JinGeneral Manager of Shenyang Sunshine Pharmaceutical Co., Ltd. · born 1981
- Mr. An YuGeneral Manager of Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. · born 1983